Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.49
RGEN's Cash-to-Debt is ranked lower than
75% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. RGEN: 1.49 )
Ranked among companies with meaningful Cash-to-Debt only.
RGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.49  Med: No Debt Max: No Debt
Current: 1.49
Equity-to-Asset 0.58
RGEN's Equity-to-Asset is ranked lower than
61% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RGEN: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
RGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.89 Max: 0.97
Current: 0.58
0.5
0.97
Interest Coverage 4.24
RGEN's Interest Coverage is ranked lower than
91% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 4.24 )
Ranked among companies with meaningful Interest Coverage only.
RGEN' s Interest Coverage Range Over the Past 10 Years
Min: 4.24  Med: 430.13 Max: 3988
Current: 4.24
4.24
3988
Piotroski F-Score: 5
Altman Z-Score: 6.88
Beneish M-Score: -2.56
WACC vs ROIC
8.73%
22.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.28
RGEN's Operating Margin % is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. RGEN: 15.28 )
Ranked among companies with meaningful Operating Margin % only.
RGEN' s Operating Margin % Range Over the Past 10 Years
Min: -27.5  Med: 15.88 Max: 186.01
Current: 15.28
-27.5
186.01
Net Margin % 11.17
RGEN's Net Margin % is ranked higher than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. RGEN: 11.17 )
Ranked among companies with meaningful Net Margin % only.
RGEN' s Net Margin % Range Over the Past 10 Years
Min: -19.38  Med: 12.03 Max: 192.3
Current: 11.17
-19.38
192.3
ROE % 7.78
RGEN's ROE % is ranked higher than
83% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. RGEN: 7.78 )
Ranked among companies with meaningful ROE % only.
RGEN' s ROE % Range Over the Past 10 Years
Min: -6.01  Med: 7.99 Max: 82.79
Current: 7.78
-6.01
82.79
ROA % 5.08
RGEN's ROA % is ranked higher than
85% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. RGEN: 5.08 )
Ranked among companies with meaningful ROA % only.
RGEN' s ROA % Range Over the Past 10 Years
Min: -5.6  Med: 6.72 Max: 75.79
Current: 5.08
-5.6
75.79
ROC (Joel Greenblatt) % 48.18
RGEN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. RGEN: 48.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -97.28  Med: 50.1 Max: 1148.92
Current: 48.18
-97.28
1148.92
3-Year Revenue Growth Rate 13.40
RGEN's 3-Year Revenue Growth Rate is ranked higher than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. RGEN: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.3  Med: 13.2 Max: 45.6
Current: 13.4
-52.3
45.6
3-Year EBITDA Growth Rate -8.90
RGEN's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. RGEN: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -68.2  Med: 3.8 Max: 115.3
Current: -8.9
-68.2
115.3
3-Year EPS without NRI Growth Rate -12.10
RGEN's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. RGEN: -12.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73  Med: 6.7 Max: 108
Current: -12.1
-73
108
GuruFocus has detected 4 Warning Signs with Repligen Corp $RGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGEN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RGEN Guru Trades in Q1 2016

Chuck Royce 100,000 sh (New)
Columbia Wanger 604,635 sh (New)
Joel Greenblatt 37,195 sh (+55.29%)
Jim Simons 982,404 sh (+25.61%)
Paul Tudor Jones 9,490 sh (-25.92%)
» More
Q2 2016

RGEN Guru Trades in Q2 2016

Joel Greenblatt 59,717 sh (+60.55%)
Chuck Royce 159,000 sh (+59.00%)
Paul Tudor Jones 13,444 sh (+41.66%)
Columbia Wanger 800,877 sh (+32.46%)
Jim Simons 1,124,804 sh (+14.50%)
» More
Q3 2016

RGEN Guru Trades in Q3 2016

Joel Greenblatt 140,516 sh (+135.30%)
Chuck Royce 199,000 sh (+25.16%)
Paul Tudor Jones Sold Out
Jim Simons 1,077,700 sh (-4.19%)
Columbia Wanger 559,471 sh (-30.14%)
» More
Q4 2016

RGEN Guru Trades in Q4 2016

Joel Greenblatt 129,559 sh (-7.80%)
Jim Simons 891,600 sh (-17.27%)
Columbia Wanger 294,991 sh (-47.27%)
Chuck Royce 98,000 sh (-50.75%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NYSE:EBS, NAS:CORT, NAS:XNCR, NAS:LOXO, NAS:AIMT, NAS:INSM, NAS:CHRS, OTCPK:PFSCF, NAS:ALDR, NAS:BPMC, NAS:FPRX, NAS:XLRN, NAS:FOLD, NAS:FWP, OTCPK:GNFTF, NAS:EPZM, NAS:PBYI, NAS:ACOR, OTCPK:BPMUF, NAS:DERM » details
Traded in other countries:RGN.Germany,
Headquarter Location:USA
Repligen Corp is a life sciences company engaged in the development, manufacture & sale of consumable bioprocessing products for life sciences companies & biopharmaceutical manufacturing companies. It also supplies growth factor products.

Repligen Corp is a bioprocessing company that develops, produces and commercializes innovative biologic drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's total revenue is generated in Sweden, followed by the United States, United Kingdom, and other regions.

Ratios

vs
industry
vs
history
PE Ratio 106.24
RGEN's PE Ratio is ranked lower than
87% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. RGEN: 106.24 )
Ranked among companies with meaningful PE Ratio only.
RGEN' s PE Ratio Range Over the Past 10 Years
Min: 3.19  Med: 46.98 Max: 534
Current: 106.24
3.19
534
PE Ratio without NRI 106.24
RGEN's PE Ratio without NRI is ranked lower than
85% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. RGEN: 106.24 )
Ranked among companies with meaningful PE Ratio without NRI only.
RGEN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.19  Med: 57.72 Max: 99999999.99
Current: 106.24
3.19
99999999.99
PB Ratio 7.03
RGEN's PB Ratio is ranked lower than
75% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. RGEN: 7.03 )
Ranked among companies with meaningful PB Ratio only.
RGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 2.86 Max: 12.19
Current: 7.03
1.42
12.19
PS Ratio 11.41
RGEN's PS Ratio is ranked higher than
53% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. RGEN: 11.41 )
Ranked among companies with meaningful PS Ratio only.
RGEN' s PS Ratio Range Over the Past 10 Years
Min: 2.73  Med: 6.75 Max: 20.38
Current: 11.41
2.73
20.38
Price-to-Free-Cash-Flow 381.09
RGEN's Price-to-Free-Cash-Flow is ranked lower than
97% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. RGEN: 381.09 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.2  Med: 39.73 Max: 756.91
Current: 381.09
3.2
756.91
Price-to-Operating-Cash-Flow 161.57
RGEN's Price-to-Operating-Cash-Flow is ranked lower than
94% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. RGEN: 161.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.14  Med: 34.27 Max: 99999999.99
Current: 161.57
3.14
99999999.99
EV-to-EBIT 74.05
RGEN's EV-to-EBIT is ranked lower than
87% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. RGEN: 74.05 )
Ranked among companies with meaningful EV-to-EBIT only.
RGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -633.3  Med: 15.2 Max: 650.3
Current: 74.05
-633.3
650.3
EV-to-EBITDA 55.05
RGEN's EV-to-EBITDA is ranked lower than
82% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. RGEN: 55.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8133.7  Med: 17.8 Max: 3669.8
Current: 55.05
-8133.7
3669.8
PEG Ratio 2.62
RGEN's PEG Ratio is ranked lower than
60% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. RGEN: 2.62 )
Ranked among companies with meaningful PEG Ratio only.
RGEN' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0.67 Max: 2.75
Current: 2.62
0
2.75
Shiller PE Ratio 97.90
RGEN's Shiller PE Ratio is ranked lower than
66% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. RGEN: 97.90 )
Ranked among companies with meaningful Shiller PE Ratio only.
RGEN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.76  Med: 83.93 Max: 470
Current: 97.9
44.76
470
Current Ratio 8.74
RGEN's Current Ratio is ranked higher than
74% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. RGEN: 8.74 )
Ranked among companies with meaningful Current Ratio only.
RGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 7.61 Max: 29.8
Current: 8.74
1.57
29.8
Quick Ratio 7.57
RGEN's Quick Ratio is ranked higher than
71% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RGEN: 7.57 )
Ranked among companies with meaningful Quick Ratio only.
RGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 6.72 Max: 29.34
Current: 7.57
1.49
29.34
Days Inventory 173.02
RGEN's Days Inventory is ranked lower than
64% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. RGEN: 173.02 )
Ranked among companies with meaningful Days Inventory only.
RGEN' s Days Inventory Range Over the Past 10 Years
Min: 87.98  Med: 151.71 Max: 173.02
Current: 173.02
87.98
173.02
Days Sales Outstanding 53.05
RGEN's Days Sales Outstanding is ranked higher than
57% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. RGEN: 53.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.73  Med: 25.43 Max: 53.05
Current: 53.05
6.73
53.05
Days Payable 39.21
RGEN's Days Payable is ranked lower than
64% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. RGEN: 39.21 )
Ranked among companies with meaningful Days Payable only.
RGEN' s Days Payable Range Over the Past 10 Years
Min: 24.96  Med: 58.01 Max: 161.29
Current: 39.21
24.96
161.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.90
RGEN's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. RGEN: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18  Med: -4.1 Max: 0.3
Current: -1.9
-18
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 54.79
RGEN's Price-to-Net-Cash is ranked lower than
92% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. RGEN: 54.79 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RGEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.6  Med: 7.12 Max: 54.79
Current: 54.79
2.6
54.79
Price-to-Net-Current-Asset-Value 18.55
RGEN's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. RGEN: 18.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RGEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.28  Med: 4.87 Max: 18.55
Current: 18.55
2.28
18.55
Price-to-Tangible-Book 14.94
RGEN's Price-to-Tangible-Book is ranked lower than
87% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. RGEN: 14.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.78  Med: 3.77 Max: 14.94
Current: 14.94
1.78
14.94
Price-to-Intrinsic-Value-Projected-FCF 4.04
RGEN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
58% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. RGEN: 4.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RGEN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 1.4 Max: 4.04
Current: 4.04
0.81
4.04
Price-to-Median-PS-Value 1.69
RGEN's Price-to-Median-PS-Value is ranked lower than
79% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. RGEN: 1.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.15 Max: 9.73
Current: 1.69
0.24
9.73
Price-to-Graham-Number 8.27
RGEN's Price-to-Graham-Number is ranked lower than
88% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. RGEN: 8.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RGEN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.65  Med: 3.8 Max: 8.27
Current: 8.27
0.65
8.27
Earnings Yield (Greenblatt) % 1.35
RGEN's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. RGEN: 1.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.3 Max: 9.9
Current: 1.35
0.2
9.9

More Statistics

Revenue (TTM) (Mil) $104.5
EPS (TTM) $ 0.33
Beta1.10
Short Percentage of Float10.67%
52-Week Range $21.11 - 36.10
Shares Outstanding (Mil)33.85
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen to Report First Quarter 2017 Financial Results Apr 21 2017 
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
ETFs with exposure to Repligen Corp. : April 21, 2017 Apr 21 2017
Repligen to Report First Quarter 2017 Financial Results Apr 21 2017
Stocks Flat But Alphabet, Lockheed Martin Hit New Highs Mar 17 2017
Top 3 Healthcare Penny Stocks for 2017 Mar 01 2017
Repligen Corp. :RGEN-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 Feb 23 2017
Edited Transcript of RGEN earnings conference call or presentation 22-Feb-17 1:30pm GMT Feb 22 2017
Repligen beats 4Q profit forecasts Feb 22 2017
Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017 Feb 22 2017
Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : February 21, 2017 Feb 21 2017
Repligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance... Feb 16 2017
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin... Jan 04 2017
Repligen Corp. – Value Analysis (NASDAQ:RGEN) : January 3, 2017 Jan 03 2017
3 Overlooked Drug Stocks to Watch Out for in 2017 Jan 03 2017
Repligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : January 2, 2017 Jan 02 2017
Blog Coverage Repligen Acquires Maker of Tangential Flow Filtration Cassettes Dec 16 2016
Novasep Sells U.S. Subsidiary TangenX Technology Corporation, Innovator in Tangential Flow... Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)